IOL Chemicals & Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- IOL Chemicals & Pharmaceuticals Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 0.3%.
- Its expenses for the quarter were down by 1.3% QoQ and up 0.6% YoY.
- The net profit increased 7.2% QoQ and decreased 11.0% YoY.
- The earnings per share (EPS) of IOL Chemicals & Pharmaceuticals Ltd stood at 3.5 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 527.37 | 532.18 | 528.77 | -0.9% | -0.3% |
Total Expenses | 499.57 | 506.24 | 496.68 | -1.3% | 0.6% |
Profit Before Tax | 27.80 | 25.94 | 32.09 | 7.2% | -13.4% |
Tax | 7.27 | 6.79 | 9.01 | 7.1% | -19.3% |
Profit After Tax | 20.53 | 19.15 | 23.08 | 7.2% | -11.0% |
Earnings Per Share | 3.50 | 3.30 | 3.90 | 6.1% | -10.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
IOL Chemicals & Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing and selling of active pharmaceutical ingredients (APIs) and specialty chemicals. The company is recognized for its integrated production capabilities that span the entire manufacturing process from basic chemicals to advanced pharmaceuticals. IOL Chemicals & Pharmaceuticals Ltd has a strong presence in both domestic and international markets, supplying its products to various pharmaceutical companies around the globe. As of October 2023, there is no recent major development reported in the public domain for IOL Chemicals & Pharmaceuticals Ltd.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), IOL Chemicals & Pharmaceuticals Ltd reported a total income of ₹527.37 crores. This marks a slight decrease of 0.9% on a quarter-over-quarter (QoQ) basis compared to ₹532.18 crores in Q2FY25, and a marginal decline of 0.3% year-over-year (YoY) from ₹528.77 crores in Q3FY24. These figures reflect a stable revenue stream with minor fluctuations over the respective periods. The company's revenue performance indicates steadiness in its income generation, aligning closely with its previous financial quarters.
Profitability
For Q3FY25, the company achieved a profit before tax of ₹27.80 crores. This represents a 7.2% increase QoQ from ₹25.94 crores in Q2FY25, although it signifies a 13.4% decline YoY from ₹32.09 crores in Q3FY24. The tax expense for the quarter stood at ₹7.27 crores, up by 7.1% QoQ compared to ₹6.79 crores in the previous quarter, and down by 19.3% YoY from ₹9.01 crores in the same quarter of the previous year. Consequently, the profit after tax for Q3FY25 was ₹20.53 crores, showing a growth of 7.2% QoQ from ₹19.15 crores in Q2FY25, but reflecting an 11.0% decrease YoY from ₹23.08 crores in Q3FY24. The earnings per share was ₹3.50 in Q3FY25, which increased by 6.1% QoQ from ₹3.30 and decreased by 10.3% YoY from ₹3.90 in Q3FY24.
Operating Metrics
The total expenses for Q3FY25 were reported at ₹499.57 crores, which is 1.3% lower than the ₹506.24 crores in Q2FY25. However, compared to Q3FY24, there is a slight increase of 0.6% from ₹496.68 crores. This modest reduction in expenses QoQ, coupled with a stable income, has contributed to the improvement in profitability metrics over the quarter. The observed YoY increase in expenses is aligned with the broader industry trends of rising input costs. Despite these cost dynamics, the company's operational efficiency appears effective in maintaining profitability levels over time, as evidenced by the QoQ improvements in profit before and after tax.
